Authors
Binbin Shi, Qingjun Yang, Feiyu Wang, Jijun Song, Youwei Bao
Published in
Immunity, inflammation and disease. Volume 14. Issue 11.
Abstract
Allergic rhinitis (AR) is a global disease characterized by Th2 inflammation and eosinophil infiltration. Triptolide (TP), the main active component of Tripterygium wilfordii, has significant anti-inflammatory effects, but its multi-target mechanism for treating AR remains unclear.
To analyze the mechanism of TP against AR through network pharmacology prediction and experimental validation.
Core targets and pathways of TP were screened using network pharmacology. A house dust mite (HDM)-induced AR mouse model (BALB/c, n = 6/group) was established and treated with TP (10/20/30 μg/kg) or dexamethasone (2 mg/kg). Serum levels of IL-4, IL-5, IL-13, and IgE were detected by ELISA. Pathological changes in nasal and lung tissues were assessed by HE staining. P38 MAPK, p-p38 MAPK, PTGS2, and VCAM-1 were analyzed by Western blot (WB) and qPCR. In vitro experiments used HDM-stimulated human nasal epithelial cells (HNEPCs) to evaluate inflammatory markers.
Network analysis identified 33 shared targets, including MAPK14, MAPK1, NFKB1, PTGS2, and VCAM1, which were enriched in MAPK, TNF, NF-κB, and IL-17 signaling pathways. In vivo experiments showed that TP (20 µg/kg) significantly reduced IgE and Th2 cytokine levels, inhibited eosinophil infiltration, and was associated with suppressed p38 MAPK phosphorylation.
TP alleviates Th2 inflammation and immune imbalance, and these effects are associated with suppression of the p38 MAPK signaling pathway and downstream PTGS2/VCAM-1. Whether TP can serve as an alternative treatment strategy for steroid-dependent AR requires further validation.
PMID:
43043085
Bibliographic data and abstract were imported from PubMed on 17 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0